NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED BREAST-CANCER

Thirty-eight patients with locally advanced breast cancer (Stage III) were treated over a 3-year period. All patients initially received two cycles of CMF (cyclophosphamide, 100 mg/m(2) p.o. dl-14; methotrexate 30mg/m(2) intravenously (iv), d1 and d8., 5 Fluorouracil 500 mg/m(2) iv d1 and d8). They were then subjected to surgery and external beam i rradiation to the chest field and drainage areas. Four more cycles of chemotherapy completed the treatment protocol. A response to initial c hemotherapy was seen in 75.7% patients, with two patients achieving a complete response. No patient had disease progression while on chemoth erapy. Tumor reduction of a degree to allow breast conservation proced ures was seen in eight patients. The chemotherapy was well tolerated. Twelve patients failed to complete the treatment protocol. Follow-up f or the remaining 26 ranges from 9-40 months (mean 18 months). Ten pati ents developed a recurrence. Of those, only one had isolated local rec urrence, two had local and systemic recurrence, and seven had systemic disease alone. Patients with recurrence were salvaged with further ch emotherapy (Adriamycin and cyclophosphamide). (C) 1996 Wiley-Liss, Inc .